NewAmsterdam Pharma Company N.V. (NAMS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Naarden, Netherlands. Der aktuelle CEO ist Michael Harvey Davidson Facp..
NAMS hat IPO-Datum 2021-02-09, 68 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $3.96B.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands, dedicated to developing treatments for metabolic diseases. The company's lead investigational candidate, obicetrapib, is a novel selective inhibitor of Cholesteryl Ester Transfer Protein (CETP) that has demonstrated clinical efficacy in reducing low-density lipoprotein cholesterol (LDL-C) while substantially increasing high-density lipoprotein cholesterol (HDL-C). This dual mechanism addresses a significant unmet medical need in lipid management and cardiovascular disease prevention. NewAmsterdam is focused on advancing obicetrapib through clinical development to improve patient outcomes in metabolic disease populations.
